These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 14767734)

  • 1. Role of positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer.
    Yoshioka M; Sato T; Furuya T; Shibata S; Andoh H; Asanuma Y; Hatazawa J; Shimosegawa E; Koyama K; Yamamoto Y
    J Gastroenterol; 2004 Jan; 39(1):50-5. PubMed ID: 14767734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET.
    Higashi T; Sakahara H; Torizuka T; Nakamoto Y; Kanamori S; Hiraoka M; Imamura M; Nishimura Y; Tamaki N; Konishi J
    J Nucl Med; 1999 Sep; 40(9):1424-33. PubMed ID: 10492360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
    Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
    Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study.
    Maisey NR; Webb A; Flux GD; Padhani A; Cunningham DC; Ott RJ; Norman A
    Br J Cancer; 2000 Aug; 83(3):287-93. PubMed ID: 10917540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.
    Imdahl A; Nitzsche E; Krautmann F; Högerle S; Boos S; Einert A; Sontheimer J; Farthmann EH
    Br J Surg; 1999 Feb; 86(2):194-9. PubMed ID: 10100786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
    Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of 11-C-methionine positron emission tomography for the delineation of the tumor volume in pharyngo-laryngeal squamous cell carcinoma: comparison with FDG-PET and CT.
    Geets X; Daisne JF; Gregoire V; Hamoir M; Lonneux M
    Radiother Oncol; 2004 Jun; 71(3):267-73. PubMed ID: 15172141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modalities for evaluating chemotherapeutic efficacy and survival time in patients with advanced pancreatic cancer: comparison between FDG-PET, CT, and serum tumor markers.
    Kuwatani M; Kawakami H; Eto K; Haba S; Shiga T; Tamaki N; Asaka M
    Intern Med; 2009; 48(11):867-75. PubMed ID: 19483354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
    Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers].
    Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
    Cancer Radiother; 2005 Sep; 9(5):304-15. PubMed ID: 16087377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of computed tomography (CT) and 18F-deoxyglucose positron emission tomography (FDG-PET) image fusion for conformal radiotherapy in esophageal carcinoma].
    Moureau-Zabotto L; Touboul E; Lerouge D; Deniaud-Alexandre E; Grahek D; Foulquier JN; Petenief Y; Grès B; El Balaa H; Kerrou K; Montravers F; Keraudy K; Tiret E; Gendre JP; Grange JD; Hourry S; Talbot JN
    Cancer Radiother; 2005 May; 9(3):152-60. PubMed ID: 16023043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy.
    Allal AS; Dulguerov P; Allaoua M; Haenggeli CA; El-Ghazi el A; Lehmann W; Slosman DO
    J Clin Oncol; 2002 Mar; 20(5):1398-404. PubMed ID: 11870185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma.
    Moureau-Zabotto L; Touboul E; Lerouge D; Deniaud-Alexandre E; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Kerrou K; Montravers F; Keraudy K; Tiret E; Gendre JP; Grange JD; Houry S; Talbot JN
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):340-5. PubMed ID: 16168829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.